Form 990 for tax year 2024
Filed by NATIONAL PEDIATRIC CANCER FOUNDATION INC.
Totals
- Total revenue
- $4,449,969
- Total expenses
- $5,723,050
- Contributions and grants received
- $4,219,467
- Grants paid
- $3,441,620
- Program service revenue
- $0
- Investment income
- $87,081
- Other revenue
- $143,421
- Total assets, end of year
- $6,202,847
- Total liabilities, end of year
- $1,059,559
- Net assets or fund balances, end of year
- $5,143,288
- Program services expenses (Part IX)
- $5,120,886
- Management and general expenses
- $246,144
- Fundraising expenses
- $356,020
- Program service expenses (Part III)
- $5,120,886
Program services were 89.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1c , Fundraising events
$861,586
-
1f , All other contributions, gifts and grants
$3,357,881
-
1g , Noncash contributions included above
$10,622
-
3 , Investment income
total $129,377 · excluded $129,377
-
7a , Gross sales of assets other than inventory
securities $963,645
-
7b , Less cost or other basis and sales expenses
securities $1,005,941
-
7c , Gain or loss
securities -$42,296
-
7d , Net gain or loss
total -$42,296 · excluded -$42,296
-
8a , Fundraising events: gross income
$1,917,654
-
8a , Fundraising events: contributions included on line 1c
$861,586
-
8b , Fundraising events: direct expenses
$1,782,971
-
8c , Net income from fundraising events
total $134,683 · excluded $134,683
-
11a , Other revenue: MISCELLANEOUS REVNEUE
total $8,738 · excluded $8,738
-
11e , Other revenue, total
$8,738
Functional expenses
Part IX, the statement of functional expenses.
-
1 , Grants to domestic organizations and governments
total $3,429,303 · program services $3,429,303
-
2 , Grants to domestic individuals
total $12,317 · program services $12,317
-
5 , Compensation of officers, directors and key employees
total $492,986 · program services $414,454 · management and general $42,970 · fundraising $35,562
-
7 , Other salaries and wages
total $1,023,485 · program services $860,446 · management and general $89,208 · fundraising $73,831
-
9 , Other employee benefits
total $52,634 · program services $44,249 · management and general $4,588 · fundraising $3,797
-
10 , Payroll taxes
total $116,472 · program services $97,918 · management and general $10,152 · fundraising $8,402
-
11f , Fees: investment management
total $28,270 · management and general $28,270
-
11g , Fees: other
total $36,032 · program services $1,566 · management and general $29,708 · fundraising $4,758
-
12 , Advertising and promotion
total $132,228 · program services $1,207 · management and general $88 · fundraising $130,933
-
13 , Office expenses
total $19,313 · program services $8,968 · management and general $5,803 · fundraising $4,542
-
14 , Information technology
total $108,836 · program services $89,179 · management and general $12,673 · fundraising $6,984
-
16 , Occupancy
total $49,241 · program services $42,417 · management and general $3,420 · fundraising $3,404
-
17 , Travel
total $17,857 · program services $2,500 · management and general $3,807 · fundraising $11,550
-
19 , Conferences, conventions and meetings
total $1,623 · program services $117 · management and general $351 · fundraising $1,155
-
20 , Interest
total $28,378 · program services $24,984 · management and general $1,677 · fundraising $1,717
-
22 , Depreciation, depletion and amortization
total $52,167 · program services $45,961 · management and general $3,121 · fundraising $3,085
-
23 , Insurance
total $31,415 · program services $24,845 · management and general $4,859 · fundraising $1,711
-
24a , Other expenses: ONLINE TRANSACTION FEES
total $44,788 · program services $0 · management and general $3,154 · fundraising $41,634
-
24b , Other expenses: POSTAGE AND SHIPPING
total $27,022 · program services $5,864 · management and general $656 · fundraising $20,502
-
24c , Other expenses: CONTRACT LABOR
total $12,583 · program services $11,070 · management and general $771 · fundraising $742
-
24d , Other expenses: PRINTING AND REPRODUCTI
total $4,092 · program services $3,521 · management and general $336 · fundraising $235
-
24e , All other expenses
total $2,008 · management and general $532 · fundraising $1,476
Balance sheet
Part X, book values.
-
1 , Cash, non-interest-bearing
beginning of year $1,273,888 · end of year $581,005
-
2 , Savings and temporary cash investments
end of year $602,727
-
3 , Pledges and grants receivable
beginning of year $32,475 · end of year $21,455
-
9 , Prepaid expenses and deferred charges
beginning of year $193,136 · end of year $134,416
-
10a , Land, buildings and equipment: cost or other basis
$1,692,819
-
10b , Land, buildings and equipment: accumulated depreciation
$178,174
-
10c , Land, buildings and equipment, net
beginning of year $1,510,693 · end of year $1,514,645
-
11 , Investments: publicly traded securities
beginning of year $3,750,447 · end of year $3,050,583
-
15 , Other assets
beginning of year $270,970 · end of year $298,016
-
17 , Accounts payable and accrued expenses
beginning of year $76,027 · end of year $126,715
-
18 , Grants payable
end of year $272,704
-
19 , Deferred revenue
beginning of year $189,597 · end of year $37,743
-
23 , Secured mortgages and notes payable
beginning of year $647,870 · end of year $608,148
-
25 , Other liabilities
beginning of year $17,379 · end of year $14,249
-
27 , Net assets without donor restrictions
beginning of year $5,418,356 · end of year $4,475,544
-
28 , Net assets with donor restrictions
beginning of year $682,380 · end of year $667,744
Mission and programs · 2024
Mission
NATIONAL PEDIATRIC CANCER FOUNDATION (NPCF) IS A NONPROFIT ORGANIZATION DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER. OUR FOCUS IS TO FUND RESEARCH TO FIND LESS TOXIC, MORE TARGETED THERAPIES BY PARTNERING WITH LEADING HOSPITALS NATIONWIDE.
Activities or mission (Part I)
THE NPCF IS DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER.
-
THE NATIONAL PEDIATRIC CANCER FOUNDATION FUNDS PEDIATRIC CANCER RESEARCH WITH THE GOAL OF LEADING TO THE TREATMENT AND ELIMINATION OF PEDIATRIC CANCER WORLDWIDE.WE ACCOMPLISH OUR MISSION THROUGH OUR RESEARCH INITIATIVE, THE SUNSHINE PROJECT, AN INNOVATIVE COLLABORATION OF 40 HOSPITALS NATIONWIDE. THIS COLLABORATIVE RESEARCH MODEL IS UNIQUE AND EFFECTIVE IN ACCELERATING THE DEVELOPMENT OF NEW TREATMENTS AGAINST CHILDHOOD CANCER.SEE SCHEDULE O FOR FURTHER PROGRAM SERVICE ACCOMPLISHMENTS.IN DEVELOPING THIS COLLABORATION, THE FOUNDATION HAS BROUGHT TOGETHER SOME OF THE COUNTRY'S LEADING INVESTIGATORS AND INSTITUTIONS TO DRIVE THE PROCESS OF FINDING A CURE. INVESTIGATORS ARE PERFORMING THREE VITAL PHASES OF RESEARCH SIMULTANEOUSLY: BASIC SCIENCE, TRANSLATIONAL RESEARCH AND CLINICAL TRIALS. THESE MAJOR RESEARCH COMPONENTS NOT ONLY ALLOW DOCTORS TO IDENTIFY NEW AGENTS IN FIGHTING CANCER, BUT ALSO HELP RESEARCHERS TO UNDERSTAND THE CANCER CELLS RESPONSE TO THE DRUG. THE NATIONAL PEDIATRIC CANCER FOUNDATION IS MAKING GREAT STRIDES IN ITS MISSION TO FIND A CURE FOR CHILDHOOD CANCER.CURRENT INITIATIVES OF THE SUNSHINE PROJECT ARE AS FOLLOWS:SARCOMA TRIALS (OSTEOSARCOMA, RHABDOMYOSARCOMA, EWING SARCOMA, NON-RHABDOMYOSARCOMA); BRAIN CANCER TRIALS (MEDULLOBLASTOMA, HIGH-GRADE GLIOMA); SOLID STATE TUMORS1. EVOLUTIONARY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA - METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA (RMS) HAVE A POOR OUTCOME WHICH IS WORSENED WITH ADDITIONAL RISK FACTORS COMMONLY CALLED THE OBERLIN CRITERIA. PATIENTS THAT MEET ALL 4 OBERLIN CRITERIA HAVE AN EVENT FREE SURVIVAL (EFS) OF LESS THAN 20% AT 2 YEARS. ALL THERAPEUTIC ARMS ON THIS STUDY ARE DESIGNED TO MEET THE SAME PRIMARY AIM OF IMPROVING THE 3-YEAR EVENT FREE SURVIVAL FROM 6% TO 35% FOR THESE PATIENTS. 2. BLOOD BASED BIOMARKERS FOR MINIMAL RESIDUAL DISEASE DETECTION IN PEDIATRIC SARCOMAS - THE PURPOSE OF THIS STUDY IS TO SEE IF DETECTING CELL-FREE PLASMA TUMOR DNA (PTDNA) AND CIRCULATING TUMOR CELLS (CTC) CAN PREDICT RECURRENCE OF DISEASE IN PATIENTS WHO ARE IN RADIOGRAPHIC REMISSION 2-3 WEEKS AFTER TREATMENT. PLASMA TUMOR DNA (PTDNA) IS FREE FLOATING DNA FROM THE TUMOR FOUND IN THE BLOOD STREAM AND CIRCULATING TUMOR CELLS.3. A MULTI-INSTITUTION STUDY OF TGFB IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NK CELL INFUSIONS AS ADOPTIVE IMMUNOTHERAPY IN COMBINATION WITH GEMCITABINE AND DOCETAXEL IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC BONE AND SOFT TISSUE SARCOMAS: THE TINKS TRIAL - THE PURPOSE OF THIS TRIAL IS TO DETERMINE THE SAFETY OF THE ADDITION OF ADOPTIVE TRANSFER OF UNIVERSAL DONOR, TGFB IMPRINTED (TGFBI), EXPANDED NK CELLS TO GEMCITABINE/DOCETAXEL (GEM/DOX) FOR TREATMENT OF RELAPSED AND REFRACTORY SARCOMAS AND TO DETERMINE THE 6 MONTH PROGRESSION FREE SURVIVAL ACHIEVED WITH THIS TREATMENT.4. FEASIBILITY OF GENERATING NOVEL TRANSLATIONAL AND THERAPEUTIC STRATEGIES BASED ON A MULTICENTER, PEDIATRIC AND AYA EVOLUTIONARY TUMOR BOARD (PEDSETB) - PEDIATRIC EVOLUTIONARY TUMOR BOARD (PEDSETB) IS A MULTIDISCIPLINARY FORUM TO APPROACH AN INDIVIDUAL PATIENT'S CANCER AND PROPOSE ADDITIONAL IDEAS FOR CARE. THE PEDSETB WILL GATHER DISCIPLINES NOT OFTEN ENGAGED IN CANCER WORK AND USE INSIGHTS FROM EVOLUTION TO OPTIMALLY MODEL, RESEARCH, AND IMPACT PEDIATRIC CANCER OUTCOMES. STRATEGIES FROM PEDSETB'S PREDECESSOR HAVE BEEN INSTRUMENTAL IN THE DESIGN OF SEVERAL OF NPCF'S MOST RECENT CLINICAL TRIALS5. EVALUATION OF DIGOXIN FOR RELAPSED NON-WNT, NON-SHH MEDULLOBLASTOMA (PHASE 2 STUDY) - THIS TRIAL WILL EVALUATE THE EFFICACY OF DIGOXIN IN TREATING PATIENTS WITH RELAPSED NON-SHH, NON-WNT MEDULLOBLASTOMA AND TO DETERMINE IF DIGOXIN IMPROVES PROGRESSION FREE SURVIVAL AT 4 MONTHS AFTER INITIATION OF STUDY TREATMENT IN THIS PATIENT POPULATION. 6. METASTATIC EWING'S TRIAL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES - THIS TRIAL WILL TEST OUR ABILITY TO ADMINISTER FREQUENTLY CHANGING CHEMOTHERAPY REGIMENS, CALLED SEQUENTIAL SECOND STRIKES, TO PATIENTS WITH WIDELY METASTATIC EWING SARCOMA TO STOP ITS DEVELOPMENT OF RESISTANCE TO CHEMOTHERAPY AND IMPROVE CURE RATES.7. RNA LIPID PARTICLES TARGETING PEDIATRIC RECURRENT INTRACRANIAL MALIGNANCIES AND OTHER SYSTEMIC SOLID TUMORS - THIS TRIAL TESTS THE SAFETY, IMMUNE EFFECTS, AND POTENTIAL EFFECTIVENESS OF RNA-LOADED LIPID NANOPARTICLES (RNA-LP) VACCINES IN PATIENTS WITH RECURRENT PEDIATRIC HIGH-GRADE GLIOMA (PHGG), A TYPE OF BRAIN CANCER, AND RECURRENT OSTEOSARCOMA (OSA), A TYPE OF BONE CANCER. 8. OPEN-LABEL, COHORT-SEQUENTIAL DOSE-ESCALATION AND DOSE-CONFIRMATION PHASE 1-2 CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DOMATINOSTAT IN COMBINATION WITH SIROLIMUS IN ADOLESCENTS AND ADULTS WITH RELAPSED, REFRACTORY SARCOMA AND OSTEOSARCOMA - THIS TRIAL TESTS THE SAFETY AND EFFECTIVENESS OF TWO DRUGS, DOMATINOSTAT AND SIROLIMUS, USED TOGETHER IN PATIENTS WITH OSTEOSARCOMA AND OTHER SARCOMAS THAT HAVE COME BACK OR DON'T RESPOND TO OTHER TREATMENTS. 9. ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3'UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS - THIS STUDY HAS IDENTIFIED A NOVEL TECHNOLOGY THAT CAN CONTROL AND DEGRADE A SPECIFIC C-MYC GENE (KNOWN AS THE MASTER REGULATOR) ACROSS MANY TYPES OF CANCERS. SINCE C-MYC IS DETECTED IN 74% OF HUMAN CANCERS, THE ABILITY TO DEGRADE AND ATTACK THIS COMMON LINK HAS THE POTENTIAL TO TRANSFORM THE TREATMENT OF CANCER. 10. TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOLOGY - THIS STUDY WILL USE QUANTUM MECHANICS TO PRECISELY TARGET SPECIFIC TUMOR CELLS WITHOUT HARMING NORMAL CELLS. THE METHOD USES CONVENTIONAL CLINICAL PROCEDURES IN A NOVEL COMBINATION WITHIN A WEAK MAGNETIC FIELD, AKIN TO A REFRIGERATOR MAGNET'S, SUCH THAT IF SUCCESSFUL IT COULD BE INTRODUCED INTO ANY HOSPITAL WITHOUT MAJOR INFRASTRUCTURAL, FINANCIAL OR PROCEDURAL DIFFICULT TO TREAT CHILDREN AND EVEN INFANTS WITH MEDULLOBLASTOMA, THE MOST COMMON CHILDHOOD BRAIN CANCER.
Expenses $5,120,886 · Grants $3,441,620
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Albert SilvaALBERT SILVA
CHAIRMAN OF THE BOARD
- Total calculated
- $0
- Hours/week
- 2
-
Michael LevinMICHAEL LEVIN
PAST CHAIR
- Total calculated
- $0
- Hours/week
- 2
-
Richard HuffRICHARD HUFF
VICE CHAIRMAN
- Total calculated
- $0
- Hours/week
- 2
-
Alex SullivanALEX SULLIVAN
VICE CHAIRMAN
- Total calculated
- $0
- Hours/week
- 2
-
Jeremy PersingerJEREMY PERSINGER
TREASURER
- Total calculated
- $0
- Hours/week
- 2
-
John FitzpatrickJOHN FITZPATRICK
SECRETARY
- Total calculated
- $0
- Hours/week
- 2
-
Michael WeignerMICHAEL WEIGNER
ASSISTANT SECRETARY
- Total calculated
- $0
- Hours/week
- 2
-
Melissa DunkelMELISSA DUNKEL
CO-FOUNDER AT LARGE
- Total calculated
- $0
- Hours/week
- 1
-
Jim BassilJIM BASSIL
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Bb AbbottBB ABBOTT
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
David BoyingtonDAVID BOYINGTON
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Chris CarrereCHRIS CARRERE
DIRECTOR AT LARGE
- Total calculated
- $0
- Hours/week
- 1
-
Carrie CharlesCARRIE CHARLES
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Chad HarrodCHAD HARROD
EMERITUS
- Total calculated
- $0
- Hours/week
- 1
-
Joseph LamphierJOSEPH LAMPHIER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Jay LangfordJAY LANGFORD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Jeff MaxwellJEFF MAXWELL
DIRECTOR AT LARGE
- Total calculated
- $0
- Hours/week
- 1
-
Mark McHughMARK MCHUGH
DIRECTOR AT LARGE
- Total calculated
- $0
- Hours/week
- 1
-
Angela NorthANGELA NORTH
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Marco SchnablMARCO SCHNABL
DIRECTOR AT LARGE
- Total calculated
- $0
- Hours/week
- 1
-
Dawn Siler-NixonDAWN SILER-NIXON
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Ashlie TeelingASHLIE TEELING
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
David FrazerDAVID FRAZER
CEO
- Total calculated
- $210,377
- From this org
- $210,377
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $191,783
- Bonus
- $18,594
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $0
- Filer's total
- $210,377
-
Dawn ZachmanDAWN ZACHMAN
COO
- Total calculated
- $119,939
- From this org
- $119,939
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
-
Robert MartinROBERT MARTIN
CFO THRU OCTOBER 2024
- Total calculated
- $132,178
- From this org
- $132,178
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
-
Jennifer FinnemoreJENNIFER FINNEMORE
CFO START OCTOBER 2024
- Total calculated
- $30,492
- From this org
- $30,492
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Written employment contract
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.
-
ALBERT EINSTEIN COLLEGE OF MEDICINE
$713,110
FOR 43 CHALLENGE PROJECT - ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS AND ONE CARON META IN EWING SARCOMA TRIAL
-
IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.
-
FOR 43 CHALLENGE PROJECT - TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOBIOLOGY
-
$192,451
IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.
-
IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.
-
IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.
-
$95,071
IN SUPORT OF INKT TRIAL CONDUCTED UNDER THE SUNSHINE PROJECT
-
$91,654
IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT.
-
$64,417
IN SUPPORT OF CLINICAL TRIAL ADVANCING INKT STUDY
The 10 largest by cash amount. The API serves every itemized grant.
Fundraising and gaming
From Schedule G of this return, as filed.
- Had an agreement with a professional fundraiser (line 2a)
- Not answered
Fundraising events (Part II)
Part II has at most four columns: the two largest events, the rest together, and the total.
| Line | Event 1 FASHION FUNDS THE CURE | Event 2 FISHING FUNDS THE CURE | Other events 8 events | Total |
|---|---|---|---|---|
| Gross receipts (line 1) | $1,839,959 | $563,749 | $375,532 | $2,779,240 |
| Less contributions (line 2) | $726,238 | $81,345 | $54,003 | $861,586 |
| Gross income (line 3) | $1,113,721 | $482,404 | $321,529 | $1,917,654 |
| Cash prizes (line 4) | — | — | — | — |
| Noncash prizes (line 5) | — | — | — | — |
| Rent and facility costs (line 6) | $37,500 | $1,305 | $17,300 | $56,105 |
| Food and beverages (line 7) | — | — | — | — |
| Entertainment (line 8) | — | — | — | — |
| Other direct expenses (line 9) | $957,861 | $429,010 | $339,995 | $1,726,866 |
- Direct expenses (line 10)
- $1,782,971
- Net income (line 11)
- $134,683
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 9 October 2025
- IRS schema version
- 2024v5.2
- Source object
- 202532909349300108
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.